Onco-Nephrology Symposium 2023

---

LIVE

Friday, October 6, 2023, 7:00 AM - Saturday, October 7, 2023, 12:00 PM, Hotel ZaZa, Houston, TX


AMA PRA Category 1 Credits™ (11.50 hours), AAPA Category 1 CME (11.50 hours), ABIM MOC Part 2 (11.50 hours), ANCC - Nursing Contact Hour(s) (11.50 hours), Non-Physician Attendance (11.50 hours)

This year's comprehensive conference program caters to adult and pediatric nephrologists, nurses, and Advanced Practice Providers (APPs), offering a diverse range of topics at the intersection of cancer and kidney disease. The presentations will delve into various aspects of onconephrology research, clinical surveillance, and management of immune checkpoint inhibitor (ICI) toxicity, as well as renal implications of cellular therapies such as CAR-T cell therapy. Exploration of topics such as biomarkers and other serum markers in ICI toxicity, renal outcomes in CAR-T cell therapy, and the use of urinary T-cells in the management of ICI toxicity. Additionally, the program will address hyponatremia and electrolyte emergencies in cancer, methotrexate nephrotoxicity, and the long-term implications of childhood cancer on renal function. Throughout the conference, attendees will benefit from engaging case discussions and Q&A sessions, providing them with ample opportunities to interact with and learn from experts in the field. This dynamic and multidisciplinary approach ensures that the conference will offer something interesting and relevant for all healthcare professionals involved in the care of patients with kidney disease and cancer.

1. Gain insight into the current and future needs in Onconephrology research and their implications for clinical practice
2. Identify clinical surveillance and management strategies for Immune Checkpoint Inhibitor (ICI) toxicity, including the utility of urinary T-cells and serum biomarkers.
3. Analyze the risk of AKI and outcomes in patients with low GFR undergoing CAR-T cell therapy, and the implications of CAR-T cells for kidney transplant recipients.
4. Recognize the renal complications of thrombotic microangiopathy, graft vs host disease, and cellular therapies in hematopoietic stem cell transplantation.
5. Discuss trial design for ICI surveillance in solid organ transplant patients and understand the implications of ICI therapy in this population.
6. Manage electrolyte emergencies in cancer patients, including hyponatremia, and understand their impact on patient outcomes.

Please click on the link below to register for the Onco-Nephrology Symposium:

Onco-Nephrology Symposium Registration

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation: 
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity will award 11.50 Nursing Contact Hour(s).

American Board of Internal Medicine MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.50  MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 
The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 11.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.